{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T15:05:06Z","timestamp":1770822306183,"version":"3.50.1"},"reference-count":101,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2005,5,26]],"date-time":"2005-05-26T00:00:00Z","timestamp":1117065600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2005,7]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Essential thrombocythaemia was first described over 70\u2003years ago. This condition is dominated by thrombotic and haemorrhagic complications and, in the long\u2010term, by risk of transformation to myelofibrosis and\/or acute leukaemia. However, it is heterogeneous both clinically and biologically. Here, a review of current concepts in disease aetiology and management is offered with reference to recent focused reviews where appropriate. In addition, five specific areas are discussed in detail: the role of the trephine biopsy, the disease entity prefibrotic myelofibrosis; the recently described Janus kinase 2 (<jats:italic>JAK2<\/jats:italic>) mutations; the leukaemogenicity of hydroxyurea (hydroxycarbamide); and lastly, the implications of the results of the Medical Research Council Primary Thrombocythaemia 1 study are explored.<\/jats:p>","DOI":"10.1111\/j.1365-2141.2005.05543.x","type":"journal-article","created":{"date-parts":[[2005,7,6]],"date-time":"2005-07-06T23:25:42Z","timestamp":1120692342000},"page":"153-165","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":64,"title":["Essential thrombocythaemia: challenges and evidence\u2010based management"],"prefix":"10.1111","volume":"130","author":[{"given":"Claire N.","family":"Harrison","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2005,6,13]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1097\/00001721-200401000-00004"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0609.2001.00550.x"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(92)90017-6"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s002770050007"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-06-1909"},{"key":"e_1_2_6_7_1","first-page":"17","article-title":"Prognostic significance of bone marrow biopsy in essential thrombocythemia","volume":"84","author":"Annaloro C.","year":"1999","journal-title":"Haematologica"},{"key":"e_1_2_6_8_1","doi-asserted-by":"crossref","first-page":"3310","DOI":"10.1182\/blood.V96.10.3310","article-title":"Hypersensitivity of circulating progenitor cells to megakaryocyte growth and development factor (PEG\u2010rHu MGDF) in essential thrombocythemia","volume":"96","author":"Axelrad A.A.","year":"2000","journal-title":"Blood"},{"key":"e_1_2_6_9_1","first-page":"215","article-title":"Practice guidelines for the therapy of essential thrombocythemia. A statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation","volume":"89","author":"Barbui T.","year":"2004","journal-title":"Haematologica"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.9.2954"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)71142-9"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s002770050555"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402638"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2401270"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1997.3823196.x"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2004.05301.x"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2002.03688.x"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa042087"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0301-472X(01)00640-3"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1990.8.3.556"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199504273321704"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2005.05396.x"},{"key":"e_1_2_6_23_1","first-page":"814","article-title":"Treatment of essential thrombocythemia during pregnancy with interferon\u2010alpha","volume":"87","author":"Delage R.","year":"1996","journal-title":"Obstetrics and Gynecology"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-10-3471"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-996123"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2004.05277.x"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.13.4261"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2000.02188.x"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-01-0135"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-09-3426"},{"key":"e_1_2_6_31_1","article-title":"Anagrelide: analysis of long term safety and leukemogenic potential in myeloproliferative diseases (MPDs)","volume":"100","author":"Fruchtman S.M.","year":"2002","journal-title":"Blood"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1098-2264(199708)19:4<250::AID-GCC7>3.0.CO;2-W"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0038-1653752"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1997.d01-2127.x"},{"key":"e_1_2_6_35_1","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1182\/blood.V94.4.1480","article-title":"A single\u2010base deletion in the thrombopoietin (TPO) gene causes familial essential thrombocythemia through a mechanism of more efficient translation of TPO mRNA","volume":"94","author":"Ghilardi N.","year":"1999","journal-title":"Blood"},{"key":"e_1_2_6_36_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-996111"},{"key":"e_1_2_6_37_1","first-page":"348a","article-title":"Epidemiological, diagnostic, therapeutic and prognostic aspects of essential thrombocythaemia in a retrospective study of the GIMMC group in two thousand patients","volume":"90","author":"Gugliotta L.","year":"1997","journal-title":"Blood"},{"key":"e_1_2_6_38_1","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V104.11.1523.1523","article-title":"Bone marrow biopsy and aspirate evaluation in 90 patients with essential thrombocythaemia treated with PEG interferon alpha\u20102b. Preliminary results","volume":"104","author":"Gugliotta L.","year":"2004","journal-title":"Blood"},{"key":"e_1_2_6_39_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2003.03849.x"},{"key":"e_1_2_6_40_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V95.11.3589"},{"key":"e_1_2_6_41_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2002.03474.x"},{"key":"e_1_2_6_42_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2005.05400.x"},{"key":"e_1_2_6_43_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1998.00921.x"},{"key":"e_1_2_6_44_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V93.2.417"},{"key":"e_1_2_6_45_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1999.01667.x"},{"key":"e_1_2_6_46_1","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1055\/s-0037-1613087","article-title":"Patients with essential thrombocythaemia have an increased prevalence of antiphospholipid antibodies which may be associated with thrombosis","volume":"87","author":"Harrison C.N.","year":"2002","journal-title":"Thrombosis and Haemostasis"},{"key":"e_1_2_6_47_1","article-title":"The Medical Research Council PT1 trial in essential thrombocythemia","author":"Harrison C.N.","year":"2005","journal-title":"New England Journal of Medicine"},{"key":"e_1_2_6_48_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.6.1990"},{"key":"e_1_2_6_49_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V90.10.4031"},{"key":"e_1_2_6_50_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature03546"},{"key":"e_1_2_6_51_1","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0609.2001.00359.x"},{"key":"e_1_2_6_52_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2003.04634.x"},{"issue":"1","key":"e_1_2_6_53_1","first-page":"205a","article-title":"Familial thrombocytosis associated with overproduction of thrombopoietin due to a novel splice donor site mutation.(Abstract)","volume":"92","author":"Jorgensen M.J.","year":"1997","journal-title":"Blood"},{"key":"e_1_2_6_54_1","first-page":"1394","article-title":"Anagrelide\u2010associated cardiomyopathy in polycythemia vera and essential thrombocythemia","volume":"89","author":"Jurgens D.J.","year":"2004","journal-title":"Haematologica"},{"key":"e_1_2_6_55_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V89.1.128"},{"key":"e_1_2_6_56_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V92.4.1091"},{"key":"e_1_2_6_57_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-03-0744"},{"key":"e_1_2_6_58_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2005.05373.x"},{"key":"e_1_2_6_59_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa035572"},{"key":"e_1_2_6_60_1","volume-title":"Blood","author":"Langer C.","year":"2004"},{"key":"e_1_2_6_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0369-8114(00)00021-3"},{"key":"e_1_2_6_62_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1998.00529.x"},{"key":"e_1_2_6_63_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-07-2287"},{"key":"e_1_2_6_64_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF02982131"},{"key":"e_1_2_6_65_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-8652(199905)61:1<10::AID-AJH3>3.0.CO;2-I"},{"key":"e_1_2_6_66_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2002.03386.x"},{"key":"e_1_2_6_67_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.43.6.1107"},{"key":"e_1_2_6_68_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-004-0877-4"},{"key":"e_1_2_6_69_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199802263380903"},{"key":"e_1_2_6_70_1","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1055\/s-0038-1657600","article-title":"Therapeutic dilemmas: balancing the risks of bleeding, thrombosis, and leukemic transformation in myeloproliferative disorders (MPD)","volume":"78","author":"Murphy S.","year":"1997","journal-title":"Thrombosis and Haemostasis"},{"key":"e_1_2_6_71_1","doi-asserted-by":"crossref","first-page":"3370","DOI":"10.1182\/blood.V90.9.3370","article-title":"Treatment of polycythemia vera: the use of hydroxyurea and pipobroman in 292 patients under the age of 65\u2003years","volume":"90","author":"Najean Y.","year":"1997","journal-title":"Blood"},{"key":"e_1_2_6_72_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1996.d01-1690.x"},{"key":"e_1_2_6_73_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-8652(199601)51:1<79::AID-AJH13>3.0.CO;2-6"},{"key":"e_1_2_6_74_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.0007-1048.2002.03367.x"},{"key":"e_1_2_6_75_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1999.01653.x"},{"key":"e_1_2_6_76_1","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.5.8.1781"},{"key":"e_1_2_6_77_1","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.5.5.1009"},{"key":"e_1_2_6_78_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19910515)67:10<2658::AID-CNCR2820671042>3.0.CO;2-C"},{"key":"e_1_2_6_79_1","first-page":"18","article-title":"Is ticlopidine a safe alternative to aspirin for management of myeloproliferative disorders?","volume":"78","author":"Ruggeri M.","year":"1993","journal-title":"Haematologica"},{"key":"e_1_2_6_80_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1998.01021.x"},{"key":"e_1_2_6_81_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.10153"},{"key":"e_1_2_6_82_1","first-page":"492","article-title":"Diagnosis of essential thrombocythemia at platelet counts between 400 and 600\u2003\u00d7\u200310(9)\/L. Gruppo Italiano Malattie Mieloproliferative Croniche (GIMMC)","volume":"85","author":"Sacchi S.","year":"2000","journal-title":"Haematologica"},{"key":"e_1_2_6_83_1","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V104.11.1518.1518","article-title":"A phase II trial of pegylated interferon a\u20102b in polycythaemia vera and essential thrombocythaemia. Clinical responses, effects on PRV\u20101 expression and impact upon quality of life","volume":"104","author":"Samuelsson J.","year":"2004","journal-title":"Blood"},{"key":"e_1_2_6_84_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428190290016809"},{"key":"e_1_2_6_85_1","doi-asserted-by":"publisher","DOI":"10.1016\/0165-4608(89)90127-1"},{"key":"e_1_2_6_86_1","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1182\/blood.V100.5.1596.h81702001596_1596_1601","article-title":"Predictive values of X\u2010chromosome inactivation patterns and clinicohematologic parameters for vascular complications in female patients with essential thrombocythemia","volume":"100","author":"Shih L.Y.","year":"2002","journal-title":"Blood"},{"key":"e_1_2_6_87_1","first-page":"23","article-title":"Treatment of essential thrombocythemia with anagrelide","volume":"36","author":"Silverstein M.N.","year":"1999","journal-title":"Seminars in Hematology"},{"key":"e_1_2_6_88_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V91.2.616"},{"key":"e_1_2_6_89_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V97.4.863"},{"key":"e_1_2_6_90_1","first-page":"172","article-title":"Adverse effects of antiaggregating platelet therapy in the treatment of polycythemia vera","volume":"23","author":"Tartaglia A.P.","year":"1986","journal-title":"Seminars in Hematology"},{"key":"e_1_2_6_91_1","doi-asserted-by":"publisher","DOI":"10.4065\/76.1.22"},{"key":"e_1_2_6_92_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V95.8.2569"},{"key":"e_1_2_6_93_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428190109097704"},{"key":"e_1_2_6_94_1","first-page":"1126","article-title":"Relevance of bone marrow features in the differential diagnosis between essential thrombocythemia and early stage idiopathic myelofibrosis","volume":"85","author":"Thiele J.","year":"2000","journal-title":"Haematologica"},{"key":"e_1_2_6_95_1","first-page":"1130","article-title":"Anagrelide\u2010induced bone marrow changes during therapy of chronic myeloproliferative disorders with thrombocytosis. An immunohistochemical and morphometric study of sequential trephine biopsies","volume":"88","author":"Thiele J.","year":"2003","journal-title":"Haematologica"},{"key":"e_1_2_6_96_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-003-0651-7"},{"key":"e_1_2_6_97_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1986.tb02926.x"},{"key":"e_1_2_6_98_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-04-1199"},{"key":"e_1_2_6_99_1","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V104.11.1517.1517","article-title":"PEG\u2010INtron for myeloproliferative diseases: an update of an ongoing phase II study","volume":"104","author":"Verstovsek S.","year":"2004","journal-title":"Blood"},{"key":"e_1_2_6_100_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428199609074366"},{"key":"e_1_2_6_101_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng0198-49"},{"key":"e_1_2_6_102_1","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0609.2000.90235.x"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2141.2005.05543.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2141.2005.05543.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T02:36:38Z","timestamp":1697423798000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2141.2005.05543.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,6,13]]},"references-count":101,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2005,7]]}},"alternative-id":["10.1111\/j.1365-2141.2005.05543.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2141.2005.05543.x","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,6,13]]},"assertion":[{"value":"2005-06-13","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}